Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything

Transaction worth based connected SEC Form 4 weighted mean merchantability terms ($27.80); post-transaction worth based connected March 31, 2026 marketplace adjacent ($29.61).

• What was the quality of this transaction?
  This transaction was triggered by the vesting of 8,100 restricted banal units (RSUs). When RSUs vest, the shares are treated arsenic taxable income, and it is modular signifier for insiders to merchantability a information of those shares instantly to screen the resulting taxation bill. That is precisely what happened here: Krishnan received 8,100 shares from RSU vesting and sold 2,959 of them (about 37%) successful an automatic, pre-planned transaction to fulfill the taxation withholding obligation.

• How did this transaction interaction Krishnan's wide vulnerability to Agios Pharmaceuticals?
  While nonstop communal banal holdings declined by 36.53%, Krishnan maintains important imaginable vulnerability done 16,200 restricted banal units (direct), which are convertible to communal banal successful the future.

• Did the transaction impact indirect entities oregon lone nonstop insider holdings?
  The merchantability pertained solely to nonstop ownership, with zero shares held oregon transacted via indirect entities specified arsenic household trusts oregon LLCs.

• How does this commercialized subordinate to humanities activity?
  Krishnan joined Agios connected March 5, 2025, making this transaction his one-year employment day and the archetypal vesting day of his archetypal RSU grant. This March 5, 2026, filing marks his archetypal -- and truthful acold lone -- reported sale.

* 1-year show calculated arsenic of March 31, 2026.

• Agios Pharmaceuticals develops and commercializes therapeutics targeting cellular metabolism, with its pb product, PYRUKYND (mitapivat), for hemolytic anemias, and AG-946 successful Phase I objective trials.

• The company’s concern exemplary centers connected the discovery, development, and commercialization of innovative medicines for uncommon hematologic diseases.

• Agios Pharmaceuticals chiefly serves patients with uncommon familial humor disorders, moving intimately with hematologists and specialized attraction centers.